Drug intelligence / Profile preview

gabapentin + oxaliplatin

Development stage
Unknown
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Gabapentin + oxaliplatin refers to the co-administration of gabapentin, an anticonvulsant and neuropathic pain agent, with oxaliplatin, a platinum-based chemotherapy drug. Oxaliplatin is primarily used in the treatment of colorectal cancer and works by forming DNA crosslinks that inhibit DNA replication and transcription, leading to cell death. Gabapentin acts on voltage-gated calcium channels (specifically the alpha-2-delta subunit) in the central nervous system to reduce neuronal excitability and is commonly used for neuropathic pain. The combination has been studied for its potential to reduce or prevent oxaliplatin-induced peripheral neuropathy—a common dose-limiting side effect of oxaliplatin therapy. However, clinical studies have not demonstrated significant benefit from adding gabapentin to standard regimens in reducing the incidence or severity of neurotoxicity caused by oxaliplatin[1][4][6].

02

Targets

DNACACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)

Beyond the preview

Go deeper on gabapentin + oxaliplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gabapentin + oxaliplatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call